Advertisement

Topics

Latest "A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients" News Stories

07:09 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients" found in our extensive news archives from over 250 global news sources.

More Information about A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients for you to read. Along with our medical data and news we also list A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Study On Amprenavir In Combination With Other Anti-HIV Drugs In HIV-Positive Patients Companies for you to search.

Showing "Study Amprenavir Combination With Other Anti Drugs Positive" News Articles 1–25 of 31,000+

Tuesday 25th September 2018

Newron Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference in New York

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 2018 Cantor Global Healthcare Conference in New York, NY, on Wednesday, October 3 at 3:2...


BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois Binette, Senior Vice President and BioTime’s Head of Global Development, will participate in a panel discussion at the National Eye Institute Conference at 10:15am ET/7:15am PT on Tuesday, September 25, 2018 in Bethes...

Former FDA Reviewers Brian Furmanski & Gene Williams Join Nuventra Pharma Sciences as Senior Consultants

Nuventra Pharma Sciences is pleased to announce the addition of two former FDA reviewers, Brian Furmanski, Ph.D. and


Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer; Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer

– Combination of Moran’s proven commercial and leadership skills with Pomeranz’ extensive product scale-up and operational expertise positions company for Pure-Vu® launch and sustainable growth – Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinica...

Smoking cessation services widely accepted during lung cancer screenings

A recent study found that smoking cessation services (SCS) offered at the time of lung cancer screening had a high acceptance rate by current smokers. William Evans, M.D., FRCPC, professor emeritus, McMaster University Department of Oncology, and...

NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

Data in Diverse Patient Populations from Three Continents Presented at World Congress of Endourology 2018 Annual Conference NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Ann...

NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care

Studies Show Significantly Reduced Complications, Improved Service Capacity, and Decreased Costs NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K...

Atezolizumab combination improves PFS for advanced NSCLC patients

Findings from a recent study demonstrate that the use of atezolizumab, a PD-L1 inhibitor, in combination with carboplatin plus pemetrexed as first-line therapy and pemetrexed as maintenance therapy improves progression free survival (PFS) in patients with...

Study shows women with non-small cell lung cancers live longer than men

Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, MD, the Huizenga Family Endowed Chair in Oncology Research at Loyola University...

Genervon Presents Mechanisms of Actions in Alzheimer’s Disease, Including Results Confirming that GM6 Attenuates Alzheimer’s Disease in Mouse Model, in Part by Reducing Inflammation

Following the closure of several research programs for Alzheimer’s disease, in early 2018 the FDA issued a release entitled “Draft Guidance for Industry: Early Alzheimer’s Disease: Developing Drugs for Treatment.” Encouraged by the proposed changes in the new guidance, Genervon’s research team reported new findings that its drug candidate GM6 att...

Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease. This first-in-class compound modulates a novel protein target selectively expressed in an...

AJ Lucas Group (AJL) - Positive momentum in drilling services

Edison Investment Research - Oil & Gas - AJ Lucas Group: AJ Lucas’s FY18 (to end June 2018) results highlighted a material increase in drilling service revenues (+70%) and margins (+635% EBITDA). Based on AJL’s current order book and leading indicators, management expects rig utilisation and mining sector drilling activity to be sustained in FY19 with robust margins after AJL’s e...

Applied DNA Expands Cannabis Tagging Portfolio to Address Large Growers

Applied DNA Sciences Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”) announced today that it is launching an additional system to tag the industry’s larger volume cannabis or hemp grows as part of TheraCann International’s ETCH Biotrace™ solution. On the heels of its successful showing of its first Cannabis Tagging System (CTS) in July in...

Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy

Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines Keele, Darlington and London, 25 September 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, today announced a collaboration with the Centre for Process Innovation (CPI), a UK-based techno...

Association of body temperature with obesity. The CoLaus study

Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

Charlotte Sibley joins the Board of Directors as Independent Member Paul Michalet is appointed as Chief Financial Officer Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal a...

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur... http://dlvr.it/QlGw8f pic.twitter.com/NMDcY0minN

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur... http://dlvr.it/QlGw8f  pic.twitter.com/NMDcY0minN

Zhejiang Anglikang Pharma Approved for $87 Million IPO in Shenzhen

Zhejiang Anglikang Pharmaceutical, headquartered in Shengzhou, has been approved to stage an $87 million IPO on the Shenzhen SME (small- and medium-sized enterprise) Exchange. The company is mainly known as a cephalosporin manufacturer with an annual capacity of 1500 tons. It also makes angiography and gastrointestinal drugs. Founded in 1994, Anglikang produces finished drugs, APIs and empty gelat...

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Patients with venous thromboembolism carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE concluded that the risk of recurrence is substantial.

Monday 24th September 2018

Physical activity may have beneficial effects for people with rare Alzheimer's disease

For individuals carrying a genetic mutation that causes Alzheimer's disease, engaging in at least 2.5 hours of physical activity per week may have beneficial effects on markers of Alzheimer's disease brain changes and may delay cognitive decline, according to a new study available online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association as an article in press, corrected proof.

Okayama University Research: Insights Into Mechanisms Governing the Resistance to the ...

OKAYAMA, Japan, September 25, 2018 /PRNewswire/ -- Okayama University researchers report in Biochemical and Biophysical Research Communications that the anti-cancer drug cetuximab is released with Read more...

High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients

. @fredhutch study why some cancers become resistant to immunotherapies, and use new technology to explore how #Cancer cells change under the pressure of #Immunotherapy treatments: http://ow.ly/Fg4k30lWNOh 

. @fredhutch study why some cancers become resistant to immunotherapies, and use new technology to explore how #Cancer cells change under the pressure of #Immunotherapy treatments: http://ow.ly/Fg4k30lWNOh 

The association between serum sodium concentration, hypertension and primary cardiovascular events: a retrospective cohort study

[Articles] Adverse outcomes after arthroscopic partial meniscectomy: a study of 700 000 procedures in the national Hospital Episode Statistics database for England

Overall, the risk associated with undergoing arthroscopic partial meniscectomy was low. However, some rare but serious complications (including pulmonary embolism and infection) are associated with the procedure, and the risks have not fallen with time. In view of uncertainty about the effectiveness of arthroscopic partial meniscectomy, an appreciation of relative risks is crucial for patients and...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks